Efficacy and Safety of Ulinastatin in the Treatment of Patients with Sepsis: The ADJUST Trial
Authors' conclusion
In patients with sepsis, adjunctive UTI did not reduce mortality compared with placebo. Routine use of UTI for sepsis is not supported by these findings.
Study context
- Population
- Adult ICU patients with sepsis meeting Sepsis-3 criteria within 48 hours of admissionrandomized, 340 received intervention (safety analysis), 335 in intention-to-treat analysis
- Participants
- 347 patients
- Comparison
- Adjunctive ulinastatin, compared with placebo
- UTIn = 165
- Placebon = 170reference
- Primary endpoint
- 28-day all-cause mortality
- Follow-up
- 28 days
Methodological detailsRandomization was stratified by site and septic shock
- Randomization was stratified by site and septic shock
Primary result
As reported in the abstract
28-day all-cause mortality
Each group vs placeboAbsolute difference (95% CI)P value
UTI
0.7%(−8.4% to 9.7%)
P = 0.98Each group vs placeboHazard ratio (95% CI)P value
UTI
1.03(0.66–1.61)
P = 0.90Secondary outcomes
Secondary outcomes (ICU, hospital, and 90-day mortality, and ICU/hospital length of stay)
- Secondary outcomes were similar in the two groups
Safety
| Outcome | UTI | Placebo | Absolute difference (95% CI) | P value | |
|---|---|---|---|---|---|
| Adverse eventsSafety analysis | 56.8% | 42.7% | 14.1% (3.6%–24.6%) | P = 0.009 | |
| −100102030Difference (linear scale) |
Original publication
Efficacy and Safety of Ulinastatin in the Treatment of Patients with Sepsis: The ADJUST Trial. Chest. Published 6 November 2026. doi:10. 1016/ j. chest. 2026. 10. 033
Composed by AI from the published abstract and checked against it. How Briefs are made →